The Indian drug company, Jubilant Life Sciences, has announced in
a statement that it has received final approvals for its generics Mycophenolate
Mofetil, an immuno-suppressant, and Rizatriptan, used for treatment of
migraine, from the Food and Drug Administration (FDA) of the U.S., in the
American market.
The drug firm has received final approvals for its Abbreviated
New Drug Application (ANDA) for Mycophenolate Mofetil capsules and tablets,
manufactured by the company's U.S. subsidiary branch, Jubilant Cadista
Pharmaceuticals Inc., and Rizatriptan tablets made at Jubilant Generics Ltd,
Jubilant Life Sciences said in a filing to the Bombay Stock Exchange.
FDA Nods Functional Assessment Technology from Imbio: Boon for COPD
The University of Michigan had developed a new technology 'Functional Assessment Technology', which has recently got FDA's (Food and Drug Administration) clearance.
Advertisement
The approvals are provided for Mycophenolate Mofetil in the strengths of 250 mg capsules and 500 mg tablets. For Rizatriptan tablets, the strengths of 5 mg and 10 mg were given approval. Mycophenolate Mofetil is a generic version of Roche's Cellcept while Rizatriptan tablets are generics of Merck's Maxalt tablets.
In a statement released by the Jubilant Life Sciences, it was
said that, "The current annualised US market size for Mycophenolate Mofetil USP,
250 mg capsules and 500 mg tablets, is $245 million and for Rizatriptan Tablets
5 mg and 10 mg it is $70 million, as per IMS."
The company had a total of 781 filings for formulations as of September 30, 2014, of which 322 have been approved in various regions globally. This includes 72 ANDAs filed in the US and 46 dossier filings in Europe, the company said.
Source: Medindia
The company had a total of 781 filings for formulations as of September 30, 2014, of which 322 have been approved in various regions globally. This includes 72 ANDAs filed in the US and 46 dossier filings in Europe, the company said.
Source: Medindia
LightMix Ebola Zaire Test Gets Approval from US FDA
The Swiss pharmaceutical firm Roche has received an emergency authorization from the US Food and Drug Administration (US FDA) for LightMix Ebola Zaire test.
Advertisement
 FDA's Prescription Guideline Forces Doctors to Write More LegiblyThe Indian Medical Association (IMA) has directed all doctors practicing in Maharashtra to follow the new prescription guidelines put in place by the state Food and Drugs Administration (FDA). | Advertisement
|
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they lead to higher standards of patient care.
Advertisement
Recommended Reading
Latest Drug News
Safety and effectiveness of commonly used painkillers (analgesics) for short-term relief of low back pain remain uncertain.
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.